Satisfaction and medication adherence in women with vulvovaginal atrophy: the CRETA

Figures & data

Table 1. Baseline demographics and clinical characteristics of the population.

Patient characteristic	n = 752^a
Age (years), n (%)
≤45	30 (4.0%)
46–50	63 (8.4%)
51–55	176 (23.5%)
56–60	203 (27.1%)
61–65	155 (20.7%)
66–70	75 (10.0%)
71–75	35 (4.7%)
≥76	13 (1.7%)
Weight (kg), mean ± SD	65.9 ± 10.6
Height (cm), mean ± SD	162.4 ± 7.0
BMI (kg/m^2), mean ± SD	25.0 ± 4.0
Sexual status, n (%)
Active	604 (81.2%)
Inactive	140 (18.8%)
Educational level, n (%)
Illiterate	20 (2.7%)
Primary	112 (15.0%)
Secondary	282 (37.7%)
University	334 (44.7%)
Number of children, n (%)
None	86 (11.5%)
One	187 (25.0%)
Two	325 (43.5%)
Three	116 (15.5%)
Four and above	33 (4.4%)
Provenance (regions), n (%)
Community of Madrid	201 (26.8%)
Castile and Leon	188 (25.1%)
Valencian Community	90 (12.0%)
Catalonia	81 (10.8%)
Andalusia	76 (10.1%)
Aragon	66 (8.8%)
Region of Murcia	31 (4.1%)
Asturias	7 (0.9%)
Castile La Mancha	6 (0.8%)
Canary Islands	1 (0.1%)
Ceuta or Melilla	1 (0.1%)
Basque Country	1 (0.1%)

^aDifferent missing values across the variables and groups.

BMI, body mass index; SD, standard deviation.

Figure 1. Satisfaction ratings of the different vulvovaginal atrophy therapy formulations. All differences were statistically significant (p < 0.0001). Bars represent the standard deviation from the mean.

Table 2. Responses provided by surveyed women on medication adherence.

Question	Ospemifene group		Local hormone therapy group		Vaginal moisturizer group
	n	Number of total respondents (%)	n	Number of total respondents (%)	n	Number of total respondents (%)
Are you willing to follow that treatment in the long term?	209		232		299
No		19 (9.1%)^a		32 (13.8%)^a		62 (20.7%)^b
Yes		190 (90.9%)^a		200 (86.2%)^a		237 (79.3%)^b
Do you follow the treatment according to the doctor’s instructions?	211		239		299
No		7 (3.3%)^b		51 (21.4%)^b		89 (29.8%)^b
Yes		204 (96.7%)^b		187 (78.6%)^b		210 (70.2%)^b
In the last month, how many times have you forgotten to follow the treatment?		Mean (SD)		Mean (SD)		Mean (SD)
	207	0.6 (1.3)^b	222	2.0 (2.8)^b	284	3.5 (4.3)^b

^aStatistically significant difference in comparison to the vaginal moisturizer group (p < 0.05).

^bStatistically significant difference in comparison to the other two treatment groups (p < 0.05).

SD, standard deviation.

Figure 2. Positive attributes selected by surveyed women on the different vulvovaginal atrophy therapy formulations. *p < 0.05 vs. vaginal moisturizers. ^†p < 0.05 vs. ospemifene. ^§p < 0.05 vs. local hormone therapy.